Drugs / QLS12004
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05829616 | Apr 2023 → May 2024 | neoplasm | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLS12004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05829616 ↗ |